Noninvasive real-time monitor for diagnosing and defining pressure ulcers

Download 2 pages about Pressure injuries (PI)

IR-MED developed a noninvasive real-time optical monitoring for preemptive detection and defining between deep tissue injury and stage 1 pressure ulcer by recognizing very early inflammatory processes, as soon as local subcutaneous tissue function is disturbed and cells start to disintegrate by pressure, excreted upon dependent body areas.

Pressure ulcers cause an estimated additional heavy economic burden on the medical care system of more than $9 Billion in the US alone. The best way to dramatically reduce pressure ulcer expenses is prevention by early detection.
Methods for detecting and monitoring pressure ulcers had been developed but none succeeded in providing a solution. Among them pressure ulcer detection based on skin conductivity which has relatively low resolution and is influenced by different topical skin conditions (moist, urine, feces). Deep tissue injury originates in the substratum subcutaneous skin layer (mainly muscle) while stage 1 pressure ulcer arise more superficially. One of the diagnostic problems of pressure ulcers is the ability to differentiate between deep tissue injury before it becomes visible and stage 1 pressure ulcer.
In clinical trials conducted at three nursing homes in Israel, using IR-MED noninvasive real-time monitor for pressure ulcer detection, a clear distinction between deep tissue injury and stage 1 pressure ulcer was demonstrated.
IR-MED received support from the Israeli Chief Scientist of the Ministry of Industry and Commerce to run a large clinical trial in a big rehabilitation center and a hospital in Israel. With the Israel Ministry of Health and IRB approval, the first clinical study is expected to commence during 4Q 2017. The technology is protected by one patent in provisional process and a second patent in submission.

IR-MED products are for investigational purposes only. IR-MED products are not approved to be used on humans.